Kuster H - Search Results

1

Sustained Viral Suppression With Dolutegravir Monotherapy Over 192 Weeks in Patients Starting Combination Antiretroviral Therapy During Primary Human Immunodeficiency Virus Infection (EARLY-SIMPLIFIED): A Randomized, Controlled, Multi-site, Noninferiority Trial.

West E, Zeeb M, Grube C, Kuster H, Wanner K, Scheier T, Neumann K, Jörimann L, Hampel B, Metzner KJ, Kouyos RD, Braun DL, Günthard HF. West E, et al. Among authors: kuster h. Clin Infect Dis. 2023 Oct 5;77(7):1012-1020. doi: 10.1093/cid/ciad366. Clin Infect Dis. 2023. PMID: 37338148 Free PMC article. Clinical Trial.

2

Treatment-induced decline of human immunodeficiency virus-1 p24 and HIV-1 RNA in lymphoid tissue of patients with early human immunodeficiency virus-1 infection.

Kuster H, Opravil M, Ott P, Schlaepfer E, Fischer M, Günthard HF, Lüthy R, Weber R, Cone RW. Kuster H, et al. Am J Pathol. 2000 Jun;156(6):1973-86. doi: 10.1016/S0002-9440(10)65070-5. Am J Pathol. 2000. PMID: 10854220 Free PMC article. Clinical Trial.

3

Impact of TNFalpha, LTalpha, Fc gammaRII and complement receptor on HIV-1 trapping in lymphoid tissue from HIV-infected patients.

Knuchel MC, Speck RF, Schlaepfer E, Kuster H, Ott P, Günthard HF, Opravil M, Cone RW, Weber R. Knuchel MC, et al. Among authors: kuster h. AIDS. 2000 Dec 1;14(17):2661-9. doi: 10.1097/00002030-200012010-00005. AIDS. 2000. PMID: 11125884 Clinical Trial.

4

Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection.

Trkola A, Kuster H, Leemann C, Ruprecht C, Joos B, Telenti A, Hirschel B, Weber R, Bonhoeffer S, Günthard HF; Swiss HIV Cohot Study. Trkola A, et al. Among authors: kuster h. J Virol. 2003 Dec;77(24):13146-55. doi: 10.1128/jvi.77.24.13146-13155.2003. J Virol. 2003. PMID: 14645571 Free PMC article. Clinical Trial.

5

Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point.

Trkola A, Kuster H, Leemann C, Oxenius A, Fagard C, Furrer H, Battegay M, Vernazza P, Bernasconi E, Weber R, Hirschel B, Bonhoeffer S, Günthard HF; Swiss HIV Cohort Study. Trkola A, et al. Among authors: kuster h. Blood. 2004 Sep 15;104(6):1784-92. doi: 10.1182/blood-2004-01-0251. Epub 2004 Jun 8. Blood. 2004. PMID: 15187026 Free article.

6

Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocol.

Rusert P, Fischer M, Joos B, Leemann C, Kuster H, Flepp M, Bonhoeffer S, Günthard HF, Trkola A. Rusert P, et al. Among authors: kuster h. Virology. 2004 Aug 15;326(1):113-29. doi: 10.1016/j.virol.2004.05.022. Virology. 2004. PMID: 15262500 Free article.

7

Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.

Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, Manrique A, Huber M, Rehr M, Oxenius A, Weber R, Stiegler G, Vcelar B, Katinger H, Aceto L, Günthard HF. Trkola A, et al. Among authors: kuster h. Nat Med. 2005 Jun;11(6):615-22. doi: 10.1038/nm1244. Epub 2005 May 8. Nat Med. 2005. PMID: 15880120 Clinical Trial.

8

Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.

Rusert P, Kuster H, Joos B, Misselwitz B, Gujer C, Leemann C, Fischer M, Stiegler G, Katinger H, Olson WC, Weber R, Aceto L, Günthard HF, Trkola A. Rusert P, et al. Among authors: kuster h. J Virol. 2005 Jul;79(13):8454-69. doi: 10.1128/JVI.79.13.8454-8469.2005. J Virol. 2005. PMID: 15956589 Free PMC article.

9

Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions.

Joos B, Trkola A, Fischer M, Kuster H, Rusert P, Leemann C, Böni J, Oxenius A, Price DA, Phillips RE, Wong JK, Hirschel B, Weber R, Günthard HF; Swiss HIV Cohort Study. Joos B, et al. Among authors: kuster h. J Virol. 2005 Jul;79(14):9026-37. doi: 10.1128/JVI.79.14.9026-9037.2005. J Virol. 2005. PMID: 15994796 Free PMC article.

10

Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5).

Joos B, Trkola A, Kuster H, Aceto L, Fischer M, Stiegler G, Armbruster C, Vcelar B, Katinger H, Günthard HF. Joos B, et al. Among authors: kuster h. Antimicrob Agents Chemother. 2006 May;50(5):1773-9. doi: 10.1128/AAC.50.5.1773-1779.2006. Antimicrob Agents Chemother. 2006. PMID: 16641449 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

219 results

Search Page

Filters